Dishman Carbogen Amcis Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
February 14, 2024 at 08:31 am EST
Share
Dishman Carbogen Amcis Limited reported earnings results for the third quarter and nine months ended December 31, 2023. For the third quarter, the company reported sales was INR 6,510.9 million compared to INR 6,397.9 million a year ago. Revenue was INR 6,571.4 million compared to INR 6,462.9 million a year ago. Net loss was INR 596.3 million compared to net income of INR 469.6 million a year ago. Basic loss per share from continuing operations was INR 3.8 compared to basic earnings per share from continuing operations of INR 3 a year ago. Diluted loss per share from continuing operations was INR 3.8 compared to diluted earnings per share from continuing operations of INR 3 a year ago.
For the nine months, sales was INR 19,610.6 million compared to INR 17,943.6 million a year ago. Revenue was INR 19,821.1 million compared to INR 18,153.8 million a year ago. Net loss was INR 835.3 million compared to net income of INR 409.2 million a year ago. Basic loss per share from continuing operations was INR 5.33 compared to basic earnings per share from continuing operations of INR 2.61 a year ago. Diluted loss per share from continuing operations was INR 5.33 compared to diluted earnings per share from continuing operations of INR 2.61 a year ago.
Dishman Carbogen Amcis Limited is engaged in offering contract research and manufacturing services (CRAMS), quats, specialty chemicals, Vitamins D3 and its analogues, cholesterols, and disinfectants. The Companyâs segments include CRAMS and Marketable Molecules. The CRAMS segment includes Contract Research Services and Contract Manufacturing Services, which it offers to its customers. Through its CRAMS business, the Company assists drug manufacturers in the development and optimization of processes for novel drug molecules in various stages of the development process. Its Marketable Molecules segment manufactures and supplies intermediates, chemicals, and various products for pharmaceutical, cosmetic and related industries. It has manufacturing and research facilities in India, Switzerland, France, the Netherlands, the United Kingdom and China. Its subsidiaries include CARBOGEN AMCIS (Shanghai) Co. Ltd, Dishman Infrastructure Ltd. and Dishman Carbogen Amcis (Singapore) Pte. Ltd.